CLDN18.2-TAC T cells Therapy

N/A

Report date: 2023/10/18 20:06:48

Base Information

Drug NameCLDN18.2-TAC T cells Therapy
Drug Alias NameTAC01-CLDN18.2CLDN-18.2-TAC T cellsCLDN18.2-TAC T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumoursStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTriumvira Immunologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTriumvira Immunologics IncSichuan University
Inactive CompaniesN/A
Active IndicationsSolid tumoursStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A